News Details

View all news

Sitravatinib Data To Be Highlighted At The IASLC 18th World Conference on Lung Cancer


SAN DIEGO, Sept. 6, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology biotechnology company, will highlight data on sitravatinib at the IASLC 18th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Yokohama, Japan (learn more at

Title: Evidence of Clinical Activity of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor Therapy  
Oral Presentation Session: MA 02 - Emerging Targets; Mini Oral
Presentation Topic: 04. Clinical Design, Statistics and Clinical Trials
Location: Room 511 + 512
Date and Time: October 16, 11:00 — 12:30 JST
Abstract ID: 9720
Presenter: Ticiana A. Leal, M.D.

Title: CBL Mutations as Potential Mediators of EGFR TKI Resistance Effectively Treated with Sitravatinib
Poster Session: P3.01 - Poster Session with Presenters Present
Poster Topic: 01. Advanced NSCLC
Location: Exhibit Hall, Hall B+C
Abstract ID: 9560
Presentation Date and Time: October 18, 9:30 — 16:00 JST
Presenter: Lyudmila A. Bazhenova. M.D.

About Mirati Therapeutics
Mirati Therapeutics is a clinical-stage oncology company developing targeted drugs to address the genetic, epigenetic and immunological promoters of cancer. Our precision oncology clinical programs utilize next-generation genomic testing to identify and select cancer patients who are most likely to benefit from targeted drug treatment. In immuno-oncology, we are advancing clinical programs where the ability of our drugs to improve the immune environment of tumor cells may enhance and expand the efficacy of existing immunotherapy medicines when given in combination. Our pre-clinical programs include potentially first-in-class and best-in-class drugs specifically designed to address mutations and tumors where few treatment options exist. We approach each of our discovery and development programs with a singular focus: to translate our deep understanding of the molecular drivers of cancer into better drugs and better outcomes for patients.  For more information, visit

Logo (PRNewsFoto/Mirati Therapeutics, Inc.)


View original content with multimedia:

SOURCE Mirati Therapeutics, Inc.

News Provided by Acquire Media

Categories: Press Releases
View all news